Drug
Bdc 3042
Bdc 3042: highest development phase Phase 1, developed by Bolt Biotherapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Bolt Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| BDC-3042 NCT06052852 | Phase 1 | Triple Negative Breast Cancer |
Latest
No recent events.
Follow Bdc 3042 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.